Not Yet Recruiting INTERVENTIONAL NCT07558434

CsA+EPAG/HPAG+Romiplostim N01 in Newly-diagnosed SAA/TD-NSAA

Cyclosporine + Eltrombopag/Hetrombopag + Romiplostim N01 in the Treatment of Newly-diagnosed Transfusion-dependent Non-severe Aplastic Anemia/ Severe Aplastic Anemia

Sponsor: Peking Union Medical College Hospital

Conditions Severe Aplastic Anemia (SAA) Transfusion-dependent Non-severe Aplastic Anemia

Interventions Cyclosporine (CsA) Romiplostim N01 thrombopoietin receptor agonist (TPO-RA)

Updated 1 time since 2026 Last updated: Apr 23, 2026 Started: Apr 1, 2026 Primary completion: Dec 1, 2028 Completion: Dec 1, 2029

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Severe Aplastic Anemia (SAA) and Transfusion-dependent Non-severe Aplastic Anemia and is currently actively recruiting participants. Peking Union Medical College Hospital leads this study, which shows 1 recorded version since 2026 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

1 version recorded

Not Yet Recruiting [daily]

Eligibility Summary

This study aimed to explore the efficacy and safety of cyclosporine (CsA) +eltrombopag (EPAG)/hetrombopag (HPAG)+romiplostim N01 in the treatment of newly-diagnosed transfusion-dependent aplastic anemia (TD-NSAA) and severe aplastic anemia (SAA)

Contact Information

Sponsor contact:

Peking Union Medical College Hospital

Data source: ClinicalTrials.gov

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.